IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and Ã-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: imaratx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2022 | $12.00 → $4.00 | Equal-Weight | Morgan Stanley |
| 11/30/2021 | $10.00 | Buy | HC Wainwright & Co. |
| 8/11/2021 | $33.00 → $12.00 | Overweight → Equal-Weight | Morgan Stanley |
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)